Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment.

Genes (Basel) · 2022 · PMC9601363 · PMID 36292649

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

close-to-significantp = 0.06so close (0.05 < p ≤ 0.1)

50%, p = 0.46.) Looking at the objective response rate of the alpelisib treatment, only the PIK3CA showed a close-to-significant effect, indicating that the patients with double mutations had higher response rates than those with a single PIK3CA mutation (n = 10, 100% vs. 12.5%, p = 0.06), as demonstrated in Figure 3 and Figure 4 . 4.

also in 171 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.